Personalis (NASDAQ:PSNL) posted its quarterly earnings results on Tuesday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.58), Briefing.com reports. The firm had revenue of $15.80 million for the quarter, compared to analyst estimates of $14.92 million. The firm’s revenue for the quarter was up 79.5% compared to the same quarter last year. Personalis updated its FY 2019 guidance to EPS.

NASDAQ:PSNL opened at $18.79 on Wednesday. The stock has a 50 day moving average price of $21.50. Personalis has a 52 week low of $14.25 and a 52 week high of $31.88.

In other news, Director Ken Ludlum acquired 70,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $1,190,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of research firms recently commented on PSNL. Cowen began coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating on the stock. Bank of America began coverage on Personalis in a report on Monday, July 15th. They issued a “neutral” rating and a $27.00 price objective on the stock. Oppenheimer began coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective on the stock. CIBC began coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective on the stock. Finally, Morgan Stanley began coverage on Personalis in a report on Monday, July 15th. They issued an “overweight” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $28.25.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Further Reading: What is an Initial Public Offering (IPO)?

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.